Agilent Technologies (NYSE:A) Price Target Raised to $175.00

Agilent Technologies (NYSE:A) had its price target hoisted by equities researchers at Barclays from $150.00 to $175.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective points to a potential upside of 11.31% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Piper Sandler assumed coverage on Agilent Technologies in a research report on Thursday, June 11th. They set a “neutral” rating and a $150.00 price target on the stock. Morgan Stanley upped their target price on Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Jefferies Financial Group started coverage on Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 price objective for the company. Finally, HSBC decreased their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.33.

Agilent Technologies Stock Up 1.4%

A traded up $2.13 during midday trading on Thursday, reaching $157.22. 1,992,931 shares of the company were exchanged, compared to its average volume of 2,232,849. The company has a market cap of $44.40 billion, a price-to-earnings ratio of 31.56, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25. Agilent Technologies has a one year low of $108.35 and a one year high of $163.75. The company’s fifty day moving average price is $139.16 and its 200 day moving average price is $126.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same period last year, the firm earned $1.37 earnings per share. The firm’s revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, analysts expect that Agilent Technologies will post 6.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its stake in shares of Agilent Technologies by 12,343.3% during the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after buying an additional 54,138,451 shares in the last quarter. Norges Bank bought a new stake in Agilent Technologies in the 4th quarter worth approximately $549,158,000. Bank of New York Mellon Corp raised its stake in Agilent Technologies by 87.4% during the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after purchasing an additional 2,440,360 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Agilent Technologies in the 2nd quarter valued at about $260,101,000. Finally, AQR Capital Management LLC lifted its stake in shares of Agilent Technologies by 424.1% in the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after purchasing an additional 1,652,244 shares during the last quarter. Institutional investors own 87.41% of the company’s stock.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.